PatientsVille.com Logo

CARDIAC FAILURE CONGESTIVE and Voltaren

PatientsVille

CARDIAC FAILURE CONGESTIVE Symptoms and Causes

Heart failure is a condition in which the heart can't pump enough blood to meet the body's needs. Heart failure does not mean that your heart has stopped or is about to stop working. It means that your heart is not able to pump blood the way it should. It can affect one or both sides of the heart.

The weakening of the heart's pumping ability causes

  • Blood and fluid to back up into the lungs
  • The buildup of fluid in the feet, ankles and legs - called edema
  • Tiredness and shortness of breath

Common causes of heart failure are coronary artery disease, high blood pressure and diabetes. It is more common in people who are 65 years old or older, African Americans, people who are overweight, and people who have had a heart attack. Men have a higher rate of heart failure than women.

Your doctor will diagnose heart failure by doing a physical exam and heart tests. Treatment includes treating the underlying cause of your heart failure, medicines, and heart transplantation if other treatments fail.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for CARDIAC FAILURE CONGESTIVE

CARDIAC FAILURE CONGESTIVE treatment research studies

Voltaren clinical trials, surveys and public health registries


Find Drug Side Effect reports



Voltaren Side Effects

Off Label Use (256)
Dyspnoea (171)
Therapeutic Response Unexpected (136)
Blood Creatinine Increased (129)
Aspartate Aminotransferase Increased (122)
Pain (115)
Alanine Aminotransferase Increased (114)
Nausea (114)
Pyrexia (112)
Erythema (108)
Blood Urea Increased (108)
Dizziness (107)
C-reactive Protein Increased (105)
Blood Pressure Decreased (105)
Renal Failure Acute (103)
Haemoglobin Decreased (85)
Blood Lactate Dehydrogenase Increased (84)
Anaemia (84)
Underdose (83)
Abdominal Pain Upper (81)
Diarrhoea (80)
Rash (80)
Oedema Peripheral (77)
Pruritus (74)
Loss Of Consciousness (74)
Shock (73)
Malaise (72)
Gastric Ulcer (72)
Vomiting (70)
Abdominal Pain (70)
Fall (64)
Hypotension (62)
Pain In Extremity (59)
Gastrointestinal Haemorrhage (57)
Headache (56)
Overdose (56)
Anaphylactic Shock (56)
Asthenia (54)
Blood Alkaline Phosphatase Increased (54)
Depressed Level Of Consciousness (53)
Chest Pain (52)
Melaena (51)
Blood Creatine Phosphokinase Increased (51)
Blood Bilirubin Increased (49)
Back Pain (49)
Disseminated Intravascular Coagulation (49)
Haematemesis (49)
Liver Disorder (49)
Blister (48)
Hypertension (47)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

It seems as though after I have applied the Voltaren to my hands and feet a couple of hours later or even the next day, I get a migrane headache and slowly but very surely all my joints, from my neck down to my elbows, knees, hips are especially pain

What is dyspnoae

i had heart failure last august 2010, among other tablets i have been taking emconcor. i wonder whether these tablets are responsible for making my limbs feel weak, and lightheaded.

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

<b>Describe Your Tazocin Experience Here:</b>after it was administered to my farther in hospital for the first time on day he was due to be released he had a cardiac arrest with multiple organ failure and subsequently died

had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom

<span style='font-weight: bold;'><a href='http://sideeffects101.com/drug-side-effects/lumigan-cardiac-disorder.htm' rel='nofollow'>cardiac disorder</a>, <a href='http://sideeffects101.com/drug-side-effects/lumigan-dyspnoea.htm' r

A report-I had a suppression dose of Macrobid; after 8 months much worse and after a year in fulminant hepatic failure leading to a transplant. How can these changes be spotted for women like me.

AGGRENOX SIDE EFFECT. PATIENT WAS PRESCRIBED PLAVIX. AGGRENOX WAS SUBSTITUTED. PATIENT SUFFERED ACUTE RESPIRATORY FAILURE AND CARDIO-RESPIRATORY ARREST. PATIENT WAS HOSPITALIZED. PATIENT DIED 3/29/09.

An injection of toradol in hattiesburg Forrest general Hospital resulted in complete Kidney failure with 5 days in hospital. medical records are available if proof is needed. recovered

Anything to indicate tha Xeloda causes cardiac arrest or arrhythmia? I had cardiac arrest and the doctors can find no other reason.

Been on drug since 1/20/11. er mid feb w/diagnosis of acid reflux; as time went on i have had excessive gas, leg/ankle swelling; loss of appetite; dry cough; sleepiness; lack of energy; out of breath; docs say heart failure---this is an 85 yr old man

CARDIAC FAILURE CONGESTIVE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Drug: Diclofenac Sodium Topical Gel, 1%;   Drug: Voltaren Topical Gel, 1%;   Drug: Vehicle Diclofenac Sodium Topical Gel
Outcome Measure: WOMAC Pain Score
2 Recruiting Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries
Condition: Athletic Injuries
Intervention: Drug: Diclofenac hydroxyethylpyrrolidine
Outcome Measures: Dermatologic assessment at the patch application site;   Investigator assessment of the global response to therapy on a 5-point scale;   Patient assessment of pain on a 6-point scale;   Plasma concentration of diclofenac
3 Recruiting An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
Condition: Delayed Onset Muscle Soreness
Interventions: Drug: 1% diclofenac sodium gel;   Drug: Placebo
Outcome Measure: To assess analgesic efficacy of Topical Voltaren® gel compared to placebo
4 Recruiting Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%
Conditions: Knee Pain Chronic;   Knee Injuries
Interventions: Drug: Diclofenac Cream 8%;   Drug: Diclofenac Gel 1%
Outcome Measure: Descrete Response Scale Pain Scores
5 Unknown  Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Etoricoxib;   Drug: Diclofenac
Outcome Measures: To explore the effect of Etoricoxib compared to Diclofenac on physical activity in RA subjects with Early morning pain and stiffness.;   To explore the effect of Etoricoxib compared to Diclofenac on average daily pain scores, fatigue scores, and quality of life.
6 Recruiting Efficacy of Diclofenac on Pain During Endometrial Sampling
Condition: Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Interventions: Drug: Diclofenac Potassium;   Drug: Folic Acid
Outcome Measure: Effectiveness of Diclofenac Potassium for additional acute pain control in patient undergoing fractional curettage under paracervical block due to abnormal uterine bleeding
7 Recruiting A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
Condition: Ankle Sprain
Interventions: Drug: 1% diclofenac sodium plus 3% menthol;   Drug: 1% diclofenac sodium plus 0.09% menthol;   Drug: 3% menthol;   Drug: Placebo with 0.09% menthol gel
Outcome Measures: AUC (1-3 days);   Pain Intensity Difference (PID) on movement;   PID at rest;   Pain Relief Score (PRS);   Sum of Pain Intensity Difference (SPID);   Time of Onset of Pain Relief (TOPR);   Time of Onset of Meaningful Pain Relief (TOMR);   Time of Onset of Cooling Sensation (TOCS);   Total Pain Relief (TOTPAR);   Skin Temperature;   Ankle Swelling;   Time to complete Recovery;   Patient's Global Assessment in Response to Treatment (PGART);   Adverse events (AEs)
8 Recruiting Effects of Topical Diclofenac on Tumor Metabolism
Condition: Actinic Keratoses
Intervention: Drug: 3% diclofenac in 2.5% hyaluronic acid gel
Outcome Measures: Lactate level in skin biopsies of actinic keratoses;   Lactate level in skin biopsies of healthy skin in a subpopulation;   Glycolysis-relevant proteins evaluated using PCR and Westernblot techniques;   Metabolic changes (e.g. glucose, amino acids)
9 Not yet recruiting Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers
Condition: Supersaturation and Precipitation in the Stomach
Intervention: Drug: Diclofenac potassium 50 mg
Outcome Measure: Area under the Concentration - Time Curve
10 Unknown  Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty
Conditions: Coxarthrosis;   Arthroplasties Hip Replacement;   Perioperative Blood Loss
Interventions: Drug: Etoricoxib;   Drug: Diclofenac
Outcome Measure:
11 Recruiting Diclofenac for Submassive PE
Condition: Pulmonary Embolism
Interventions: Drug: Diclofenac;   Drug: Placebo
Outcome Measure: Right ventricular dysfunction assessed by transthoracic echocardiography
12 Not yet recruiting In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice
Condition: Healthy Volunteers
Intervention: Dietary Supplement: pineapple juice (Carrefour n°1) 500 ml/day 5 days
Outcome Measures: a) AUC 4-OH-diclofenac / AUC diclofenac quantified in plasma, on days 1 (without pineapple juice) and 11 (after pretreatment with pineapple juice);   (b) AUC 4-OH-diclofenac/ AUC diclofenac quantified in urine, on days 1 (without pineapple juice) and 11 (after pretreatment with pineapple juice)
13 Unknown  The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema
Conditions: Uveitis;   Cystoid Macular Edema
Interventions: Drug: Diclophenac;   Drug: Triamcinolone
Outcome Measure:
14 Recruiting Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)
Condition: Osteoarthritis, Knee
Intervention: Drug: diclofenac diethylamine, DDEA 2.32% gel
Outcome Measures: Measure: Pain On Movement (POM);   Measure POM regarding onset of efficacy
15 Recruiting Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
Condition: Post ERCP Pancreatitis
Interventions: Drug: Diclofenac;   Drug: normal saline
Outcome Measure: Incidence of post ERCP pancreatitis
16 Unknown  Efficacy of Diclofenac BCG Irrigations
Condition: Bladder Cancer
Interventions: Drug: Abitren;   Drug: Placebo
Outcome Measures: Change in weekly COOP Questionnaire 1;   Change in weekly COOP Questionnaire 2;   Change in weekly COOP Questionnaire 3;   Change in weekly Bladder symptoms Questionnaire;   Change in weekly time schedule questionnaire
17 Recruiting Post ERCP Pancreatitis Prevention in Average Risk Patients
Condition: Pancreatitis
Intervention: Procedure: Ceftazidime
Outcome Measure: Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium
18 Unknown  Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Interventions: Drug: Bevacizumab;   Drug: Diclofenac
Outcome Measure:
19 Not yet recruiting Diclofenac add-on to Treatment as Usual for Suicidal Patients
Condition: Depression Suicidal
Interventions: Drug: sugar pill;   Drug: Diclofenac
Outcome Measures: Suicide Assessment Scale (differences in scores before and after treatment);   Montgomery Asberg Rating Scale (differences in scores before and after treatment);   Barratt Impulsiveness Scale (differences in scores before and after treatment);   Montgomery Asberg depression Ratin scale (changes in suicidality item before and after treatment);   Montgomery Asberg Rating Scale (changes in concentration item before and after treatment);   Comprehensive Psychopathological Rating Scale (changes in aggressive feelings item before and after treatment);   Comprehensive Psychopthological Rating Scale (changes in fatigue item before and after treatment)
20 Recruiting OASIS: Osteoarthritis Sensitivity Integration Study
Conditions: Osteoarthritis;   Chronic Pain
Intervention: Drug: duloxetine, diclofenac
Outcome Measure: Pain